CYC is effective and substantially safe in patients with anti-Jo1 antisynthetase syndrome with corticosteroid-refractory ILD. CYC withdrawal may be associated with ILD relapse, and low-dose CYC was effective in ILD control. Journal of Rheumatology. 02/15/2013. (Also see: Pulmonary Fibrosis Treatments)
This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.